Emcure Pharma Cuts Poviztra Price by 55%, Starting Dose Now Rs 3,999 per Month
New Delhi: Emcure Pharmaceuticals Limited has announced a major price reduction of up to 55% for the starting dose of its weight management drug Poviztra (semaglutide injection), aiming to improve patient access amid rising obesity rates in India.
The company stated that the revised pricing will come into effect from April 3, 2026, with the starting dose (0.25 mg) now available at ₹3,999 per month (₹999 per week), compared to the earlier price of ₹8,790. Overall, prices across different dosage strengths have been reduced by an average of 47%.
Poviztra®, a once-weekly semaglutide injection available in multiple strengths ranging from 0.25 mg to 2.4 mg, is administered through a pen device designed for ease of use and accurate dosing. The revised monthly prices now range from ₹3,999 for 0.25 mg to ₹8,999 for the 2.4 mg maintenance dose.
Emcure, which exclusively distributes and commercializes Poviztra® in India as a second brand of Novo Nordisk’s semaglutide, said the move is intended to expand access to a globally established therapy backed by extensive clinical and real-world evidence.
Highlighting the public health context, the company noted that India is facing a growing obesity burden, with an estimated 254 million people affected by generalized obesity and 351 million by abdominal obesity. Semaglutide, a well-studied biologic molecule with nearly a decade of global use, has been supported by close to 50 clinical trials and extensive patient exposure worldwide.
Commenting on the development, CEO and Managing Director Satish Mehta said that the price reduction is aimed at making scientifically validated weight management treatments more affordable and accessible to a wider patient population.
Obesity is associated with over 230 health complications, including cardiovascular diseases, type 2 diabetes, hypertension, fatty liver disease, osteoarthritis, polycystic ovary syndrome, kidney disease, and Alzheimer’s disease. The company emphasized that improved access to effective therapies is crucial to addressing these challenges at scale.
Emcure Pharmaceuticals, headquartered in Pune, is an R&D-driven pharmaceutical company with a presence in over 70 countries and a broad portfolio of products across multiple therapeutic segments.
